Latest News and Press Releases

-- Fireside chat, moderated by Soumit Roy, Ph.D. of JonesTrading, will be held on Wednesday, May 26, 2021 at 11:00 am ET -- -- Featured speakers will include hematologist Alan List, M.D....

Progressing ALRN-6924: on track to initiate Phase 1b randomized placebo-controlled trial in patients with p53-mutated non-small cell lung cancer in 2nd quarter 2021 with early interim read-out...

2020 marked a year of successful evolution to a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients -- Advancing selective...

WATERTOWN, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate...

-- Placebo-controlled trial anticipated to enroll 60 patients with advanced p53-mutated NSCLC undergoing treatment with first-line carboplatin plus pemetrexed -- -- Trial anticipated to begin in...

-- Several existing Aileron investors, including Satter Medical Technology Partners and Lincoln Park Capital Fund, LLC, also participated in the offering -- – Aileron plans to use net proceeds to...

WATERTOWN, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (Nasdaq: ALRN), today announced that it has entered into definitive agreements with fundamental healthcare investors...

Aileron’s 2021 strategic priorities aim to advance its vision to bring chemoprotection to all patients with p53-mutant cancers regardless of cancer indication or chemotherapy. Key anticipated...

Presented positive clinical proof-of-concept data from ongoing ALRN-6924 Phase 1b trial in patients with p53-mutated small cell lung cancer (SCLC) treated with topotecan in late-breaking presentation...

First and only chemoprotective therapy in clinical development that utilizes a biomarker strategy designed to protect patients with p53-mutated cancers from chemotherapy-induced toxicities and side...